Pharmaceuticals News and Research

RSS

Research Roundup: Medicaid co-payments, access to docs causes worse health

Disparities In Child Access To Emergency Care For Acute Oral Injury -- This study looked at the "impact of insurance status on dental practices' willingness to schedule an appointment for a child with a symptomatic fractured permanent front tooth." Six researchers posed as mothers of 10-year-old boys who all had the same injury but different coverage: Medicaid/Children's Health Insurance Program (CHIP) or private Blue Cross dental insurance.

27 May 2011

Lilly disappointed with Court's decision to grant Amylin's request for temporary restraining order

Eli Lilly and Company today commented on a ruling issued by the U.S. District Court for the Southern District of California granting a request by Amylin Pharmaceuticals for a temporary restraining order (TRO) related to litigation involving the two companies' diabetes collaboration agreement.

27 May 2011

Bacteria that infect cystic fibrosis patients could help combat MRSA

A bacteria which infects people with cystic fibrosis could help combat other antibiotic-resistant microbes, according to a team from Cardiff and Warwick Universities.

27 May 2011

Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values

The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), disclosed results from an interim analysis of the AIM-HIGH clinical trial.

27 May 2011

Appointment of drug company to GAVI board draws criticism from NGOs

The appointment of Dutch pharmaceutical company Crucell, recently acquired by Johnson & Johnson, to the board of the GAVI Alliance is "sparking concerns over conflicts of interest and demands for tougher competition to reduce prices," the Financial Times reports.

27 May 2011

NILVAD consortium awarded €6 million grant to develop new Alzheimer's disease treatment

An international research consortium led by Trinity College Dublin that aims to develop a new Alzheimer's disease treatment has just been selected for grant funding of €6 million by the European Commission Seventh Framework Programme (FP7).

27 May 2011

Transgenomic secures exclusive license from Montefiore for cancer predictive markers

Transgenomic, Inc. announced today that it has acquired an exclusive worldwide license to Montefiore Medical Center's patent application, "Method of Determining the Sensitivity of Cancer Cells to EGFR Inhibitors including cetuximab, panitumumab and erlotinib".

27 May 2011

Sanofi-Aventis, Medtronic under scrutiny in press reports

ProPublica details alleged activities by Sanofi-Aventis to influence regulators regarding its brand-name blood thinner, Lovenox, while other news outlets report on Medtronic's activities related to a biological agent used in back surgery.

27 May 2011

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

The National Heart, Lung, and Blood Institute of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular events, including heart attacks and stroke.

27 May 2011

Mylan plans to change name of Matrix Laboratories

Mylan Inc. today announced that it plans to rebrand its Hyderabad, India-based subsidiary Matrix Laboratories Limited as Mylan.

27 May 2011

ARCA plans to expand development program for Gencaro in atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it is planning to expand the development of Gencaro, its lead cardiovascular drug candidate, to atrial fibrillation, a disease that affects more than 2.4 million patients in the United States.

27 May 2011

PAREXEL, Pfizer partner to provide clinical development services

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has been selected as one of two strategic partners by Pfizer Inc. to provide clinical development services.

From Parexel 27 May 2011

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.

27 May 2011

MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults

MAP Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application to the United States Food and Drug Administration for LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine in adults.

27 May 2011

Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive breast cancer

Tigris Pharmaceuticals, Inc., today announced enrollment of its first patient in a randomized Phase 2 clinical trial of AFP-464 with or without Faslodex in estrogen receptor (ER)-positive breast cancer patients.

27 May 2011

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

BioCryst Pharmaceuticals, Inc. presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, U.K.

26 May 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology annual meeting in Chicago that indicates combining its investigational therapy afatinib with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor.

26 May 2011

Lytix Biopharma completes two LTX-109 Phase I/IIa studies in MRSA, Gram+ skin infections

The Norwegian pharmaceutical company Lytix Biopharma today announces the successful completion of two Phase I/IIa studies with the topical antimicrobial drug Lytixar - one for nasal decolonisation of MRSA / MSSA bacteria and one for treatment of Gram+ skin infections.

26 May 2011

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

Amylin Pharmaceuticals, Inc. today announced that the United States District Court for the Southern District of California issued a temporary restraining order (TRO) against Eli Lilly and Company relating to its litigation with respect to the Amylin / Lilly diabetes collaboration agreement.

26 May 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ardea Biosciences, Inc. announced that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, UK.

26 May 2011

Pharmaceuticals News and Research

Research Roundup: Medicaid co-payments, access to docs causes worse health

Lilly disappointed with Court's decision to grant Amylin's request for temporary restraining order

Bacteria that infect cystic fibrosis patients could help combat MRSA

Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values

Appointment of drug company to GAVI board draws criticism from NGOs

NILVAD consortium awarded €6 million grant to develop new Alzheimer's disease treatment

Transgenomic secures exclusive license from Montefiore for cancer predictive markers

Sanofi-Aventis, Medtronic under scrutiny in press reports

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

Mylan plans to change name of Matrix Laboratories

ARCA plans to expand development program for Gencaro in atrial fibrillation

PAREXEL, Pfizer partner to provide clinical development services

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults

Tigris Pharmaceuticals begins enrollment in AFP-464 Phase 2 trial in ER-positive breast cancer

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Lytix Biopharma completes two LTX-109 Phase I/IIa studies in MRSA, Gram+ skin infections

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence